These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4835954)

  • 21. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
    Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
    J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in hemophilia. Part III. Discussion paper: The Red Cross program.
    Greenwalt TJ
    Ann N Y Acad Sci; 1975 Jan; 240():208-12. PubMed ID: 1053865
    [No Abstract]   [Full Text] [Related]  

  • 23. Factor VIII concentrates made in the United Kingdom and the treatment of haemophilia based on studies made during 1969--72. Report of the Medical Research Council's Blood Transfusion Research Committee Working Party on the cryoprecipitate method of preparing AHF concentrates.
    Br J Haematol; 1974 Jul; 27(3):391-405. PubMed ID: 4413414
    [No Abstract]   [Full Text] [Related]  

  • 24. Prepooled cryoprecipitate for treatment of hemophilia A.
    Menitove JE; Spero JA; Richards WA; Lewis JH; Montgomery RR; Gill JC; Hasiba U; Wheeler DV; Sherwin JA; Russell-Vaskov S; Marlar RA; Maxwell NG; Aster RH
    Transfusion; 1983; 23(3):265-7. PubMed ID: 6407160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of contaminants in factor VIII preparations administered to patients with hemophilia.
    Rock GA; Farrah G; Rozon G; Smiley RK; Cole R; Villeneuve D; Tittley P
    Can Med Assoc J; 1983 Feb; 128(4):403-8. PubMed ID: 6401585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemophilia management in New Zealand: an Auckland perspective.
    Ockelford PA; Benny AG; Van de Water NS; Berry EW
    N Z Med J; 1989 Apr; 102(866):189-91. PubMed ID: 2496366
    [No Abstract]   [Full Text] [Related]  

  • 27. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycine-precipitated antihemophilic factor concentrates and their clinical use.
    Wagner RH; Roberts HR; Webster WP; Shanbrom E; Brinkhous KM
    Thromb Diath Haemorrh Suppl; 1968; 35():41-8. PubMed ID: 5761073
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of pool cryoglobulin factor 8 concentrate in the management of haemophilia.
    O'Brien JR
    Proc R Soc Med; 1967 Mar; 60(3):243-4. PubMed ID: 6020147
    [No Abstract]   [Full Text] [Related]  

  • 30. [The cryoprecipitate, plasmatic fraction rich in antihemophilic globulin (factor VIII). Its use in the treatment of hemophilia].
    Otto-Servais M; Hugues J
    Rev Med Liege; 1969 May; 24(10):401-7. PubMed ID: 5376503
    [No Abstract]   [Full Text] [Related]  

  • 31. A protocol for cryoprecipitate production.
    Burka ER; Harker LA; Kasper CK; Kevy SV; Ness PM
    Transfusion; 1975; 15(4):307-11. PubMed ID: 1166503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of donor characteristics and preparation methods on the potency of human cryoprecipitate.
    Burka ER; Puffer T; Martinez J
    Transfusion; 1975; 15(4):323-8. PubMed ID: 1166505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variables involved in cryoprecipitate production and their effect on factor VIII activity. Report of a working party of the Regional Transfusion Directors Committee.
    Br J Haematol; 1979 Oct; 43(2):287-95. PubMed ID: 508637
    [No Abstract]   [Full Text] [Related]  

  • 34. Public interest pricing of blood services.
    Cumming PD; Wallace EL; Surgenor DM; Mierzwa BD; Smith FA
    Med Care; 1974 Sep; 12(9):743-53. PubMed ID: 4415380
    [No Abstract]   [Full Text] [Related]  

  • 35. Haemophilia A and the blood transfusion service: a Scottish study.
    Cash JD; Spencely M
    Br Med J; 1976 Sep; 2(6037):682-4. PubMed ID: 974537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost of management of patients with haemophilia.
    Carter F; Forbes CD; MacFarlane JD; Prentice CR
    Br Med J; 1976 Aug; 2(6033):465-7. PubMed ID: 953611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of a single administration of cryoprotein and plasma on factor VIII in hemophilia A].
    Vlcková M; Vorlová Z
    Vnitr Lek; 1980 Nov; 26(11):1101-6. PubMed ID: 6789551
    [No Abstract]   [Full Text] [Related]  

  • 38. A high-potency, single-donor cryoprecipitate of known factor VIII content dispensed in vials.
    McLeod BC; Sassetti RJ; Cole ER; Scott JP
    Ann Intern Med; 1987 Jan; 106(1):35-40. PubMed ID: 3098152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Storage of whole blood for up to 24 hours at ambient temperature before component preparation: implementation in the Netherlands.
    Pietersz RN
    Transfusion; 2011 Jan; 51 Suppl 1():3S-6S. PubMed ID: 21223289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of qucik and slow thaw methods of producing cryoprecipitate antihaemophilic factor from fresh and 24-hour-old blood.
    Bloom AL; Giddings JC; Bevan B; Letton M; Drummond RJ
    J Clin Pathol; 1969 Jul; 22(4):447-52. PubMed ID: 5798632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.